Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib

Abstract

Keywords

cutaneous lupus drug reaction targeted therapy

Get full access to this article

View all access options for this article.

References

Lowe

Henderson

Grau

Hansen

Sontheimer

RD.

A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465-472.

Casado-Verrier

Pérez-Santos

Delgado-Mucientes

Beato-Merino

Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib. Br J Dermatol. 2014;171(6):1559-1561.

Beaver

Amiri-Kordestani

Charlab

et al . FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21(21):4760-4766.

Wiznia

Subtil

Choi

JN.

Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol. 2013;149(9):1071-1075.

Abdou

Rider

Greenwell

Kimler

BF.

Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol. 2008;35(5):797-803.